|
[1]
|
Turajlic, S., Swanton, C. and Boshoff, C. (2018) Kidney Cancer: The Next Decade. Journal of Experimental Medicine, 215, 2477-2479. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Barata, P.C. and Rini, B.I. (2017) Treatment of Renal Cell Carcinoma: Current Status and Future Directions. CA: A Cancer Journal for Clinicians, 67, 507-524. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Siegel, R.L., Miller, K.D. and Jemal, A. (2020) Cancer Statistics, 2020. CA: A Cancer Journal for Clinicians, 70, 7-30. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
American Cancer Society. Survival Rates for Kidney Cancer.
https://www.cancer.org/cancer/types/kidney-cancer/detection-diagnosis-staging/survival-rates.html#references
|
|
[5]
|
National Cancer Institute. Cancer Stat Facts: Kidney and Renal Pelvis Cancer.
https://seer.cancer.gov/statfacts/html/kidrp.html
|
|
[6]
|
Störkel, S. and van den Berg, E. (1995) Morphological Classification of Renal Cancer. World Journal of Urology, 13, 153-158. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Srigley, J.R., Delahunt, B., Eble, J.N., Egevad, L., Epstein, J.I., Grignon, D., et al. (2013) The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. American Journal of Surgical Pathology, 37, 1469-1489. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Maxwell, P.H., Wiesener, M.S., Chang, G., Clifford, S.C., Vaux, E.C., Cockman, M.E., et al. (1999) The Tumour Suppressor Protein VHL Targets Hypoxia-Inducible Factors for Oxygen-Dependent Proteolysis. Nature, 399, 271-275. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Clark, P.E. (2009) The Role of VHL in Clear-Cell Renal Cell Carcinoma and Its Relation to Targeted Therapy. Kidney International, 76, 939-945. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Nickerson, M.L., Jaeger, E., Shi, Y., Durocher, J.A., Mahurkar, S., Zaridze, D., et al. (2008) Improved Identification of Von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors. Clinical Cancer Research, 14, 4726-4734. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Brugarolas, J. (2014) Molecular Genetics of Clear-Cell Renal Cell Carcinoma. Journal of Clinical Oncology, 32, 1968-1976. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Thomas, G.V., Tran, C., Mellinghoff, I.K., Welsbie, D.S., Chan, E., Fueger, B., et al. (2005) Hypoxia-Inducible Factor Determines Sensitivity to Inhibitors of mTOR in Kidney Cancer. Nature Medicine, 12, 122-127. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Lebacle, C., Pooli, A., Bessede, T., Irani, J., Pantuck, A.J. and Drakaki, A. (2018) Epidemiology, Biology and Treatment of Sarcomatoid RCC: Current State of the Art. World Journal of Urology, 37, 115-123. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Samiei, A., Tayshetye, P., Sanguino, A., Miller, R., Lyne, J., Cohen, J., et al. (2019) The Clinical Outcome of Renal Cell Carcinoma with Rhabdoid and Sarcomatoid Differentiation. Journal of Clinical Oncology, 37, e16083. [Google Scholar] [CrossRef]
|
|
[15]
|
Herrera-Caceres, J.O. and Jewett, M.A.S. (2018) Roles for Active Surveillance in Renal Cancer. Current Opinion in Urology, 28, 375-382. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Rini, B.I., Dorff, T.B., Elson, P., Rodriguez, C.S., Shepard, D., Wood, L., et al. (2016) Active Surveillance in Metastatic Renal-Cell Carcinoma: A Prospective, Phase 2 Trial. The Lancet Oncology, 17, 1317-1324. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Verhoeff, S., van Es, S.C., Elias, S.G., Gerritse, S., Angus, L., Oosting, S., et al. (2020) Prediction of Watchful Waiting in Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma Patients with a Good or Intermediate Prognosis. Journal of Clinical Oncology, 38, 5079-5079. [Google Scholar] [CrossRef]
|
|
[18]
|
Park, I., Lee, J., Ahn, J., Lee, D., Lee, K., Jeong, I.G., et al. (2014) Active Surveillance for Metastatic or Recurrent Renal Cell Carcinoma. Journal of Cancer Research and Clinical Oncology, 140, 1421-1428. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Kushnir, I., Basappa, N.S., Ghosh, S., Lalani, A.A., Soulieres, D., Bjarnason, G.A., et al. (2019) Active Surveillance in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis). Journal of Clinical Oncology, 37, 4516-4516. [Google Scholar] [CrossRef]
|
|
[20]
|
ASCO 2019: Active Surveillance in Metastatic Renal Cell Carcinoma: Results from the Canadian Kidney Cancer Information System.
https://www.urotoday.com/conference-highlights/asco-2019-annual-meeting/asco-2019-kidney-cancer/113043-asco-2019-active-surveillance-in-metastatic-renal-cell-carcinoma-results-from-the-canadian-kidney-cancer-information-system.html
|
|
[21]
|
Motzer, R.J. and Russo, P. (2018) Cytoreductive Nephrectomy—Patient Selection Is Key. New England Journal of Medicine, 379, 481-482. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Flanigan, R.C., Salmon, S.E., Blumenstein, B.A., Bearman, S.I., Roy, V., McGrath, P.C., et al. (2001) Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer. New England Journal of Medicine, 345, 1655-1659. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Mickisch, G., Garin, A., van Poppel, H., de Prijck, L. and Sylvester, R. (2001) Radical Nephrectomy Plus Interferon-Alfa-Based Immunotherapy Compared with Interferon Alfa Alone in Metastatic Renal-Cell Carcinoma: A Randomised Trial. The Lancet, 358, 966-970. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Franklin, J.R., Figlin, R., Rauch, J., Gitlitz, B. and Belldegrun, A. (1996) Cytoreductive Surgery in the Management of Metastatic Renal Cell Carcinoma: The UCLA Experience. Seminars in Urologic Oncology, 14, 230-236.
|
|
[25]
|
Pindoria, N., Raison, N., Blecher, G., Catterwell, R. and Dasgupta, P. (2017) Cytoreductive Nephrectomy in the Era of Targeted Therapies: A Review. BJU International, 120, 320-328. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Grant, M., Szabados, B., Kuusk, T., Powles, T. and Bex, A. (2020) Cytoreductive Nephrectomy: Does CARMENA (Cancer du Rein Metastatique Nephrectomie et Antiangiogéniques) Change Everything? Current Opinion in Urology, 30, 36-40. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Kokorovic, A. and Rendon, R.A. (2019) Cytoreductive Nephrectomy in Metastatic Kidney Cancer: What Do We Do Now? Current Opinion in Supportive and Palliative Care, 13, 255-261. [Google Scholar] [CrossRef]
|
|
[28]
|
Alhalabi, O., Karam, J.A. and Tannir, N.M. (2019) Evolving Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma of Variant Histology. Current Opinion in Urology, 29, 521-525. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Graham, J., Bhindi, B. and Heng, D.Y.C. (2019) The Evolving Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma. Current Opinion in Urology, 29, 507-512. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Méjean, A., Ravaud, A., Thezenas, S., Colas, S., Beauval, J., Bensalah, K., et al. (2018) Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. New England Journal of Medicine, 379, 417-427. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Hsiang, W.R., Kenney, P.A. and Leapman, M.S. (2020) Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma. Current Oncology Reports, 22, Article No. 35. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Mejean, A., Thezenas, S., Chevreau, C., Bensalah, K., Geoffrois, L., Thiery-Vuillemin, A., et al. (2019) Cytoreductive Nephrectomy (CN) in Metastatic Renal Cancer (mRCC): Update on Carmena Trial with Focus on Intermediate Imdc-Risk Population. Journal of Clinical Oncology, 37, 4508. [Google Scholar] [CrossRef]
|
|
[33]
|
Lázaro, M., Valderrama, B.P., Suárez, C., de-Velasco, G., Beato, C., Chirivella, I., et al. (2020) SEOM Clinical Guideline for Treatment of Kidney Cancer (2019). Clinical and Translational Oncology, 22, 256-269. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Massari, F., Di Nunno, V., Gatto, L., Santoni, M., Schiavina, R., Cosmai, L., et al. (2018) Should CARMENA Really Change Our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy. Targeted Oncology, 13, 705-714. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
AS-CO2019: Update on the CARMENA Trial with Focus on Intermediate IMDC-Risk Population: Cytoreductive Nephrectomy in Metastatic Renal Cancer.
https://www.urotoday.com/conference-highlights/asco-2019-annual-meeting/asco-2019-kidney-cancer/113069-asco-2019-cytoreductive-nephrectomy-in-metastatic-renal-cancer-update-on-carmena-trial-with-focus-on-intermediate-imdc-risk-population.html
|
|
[36]
|
Kavolius, J.P., Mastorakos, D.P., Pavlovich, C., Russo, P., Burt, M.E. and Brady, M.S. (1998) Resection of Metastatic Renal Cell Carcinoma.. Journal of Clinical Oncology, 16, 2261-2266. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Alt, A.L., Boorjian, S.A., Lohse, C.M., Costello, B.A., Leibovich, B.C. and Blute, M.L. (2011) Survival after Complete Surgical Resection of Multiple Metastases from Renal Cell Carcinoma. Cancer, 117, 2873-2882. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
You, D., Lee, C., Jeong, I.G., Song, C., Lee, J., Hong, B., et al. (2016) Impact of Metastasectomy on Prognosis in Patients Treated with Targeted Therapy for Metastatic Renal Cell Carcinoma. Journal of Cancer Research and Clinical Oncology, 142, 2331-2338. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Palumbo, C., Pecoraro, A., Knipper, S., Rosiello, G., Tian, Z., Shariat, S.F., et al. (2019) Survival and Complication Rates of Metastasectomy in Patients with Metastatic Renal Cell Carcinoma Treated Exclusively with Targeted Therapy: A Combined Population-Based Analysis. Anticancer Research, 39, 4357-4361. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Ouzaid, I., Capitanio, U., Staehler, M., Wood, C.G., Leibovich, B.C., Ljungberg, B., et al. (2019) Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review. European Urology Oncology, 2, 141-149. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Appleman, L.J., Puligandla, M., Pal, S.K., Harris, W., Agarwal, N., Costello, B.A., et al. (2019) Randomized, Double-Blind Phase III Study of Pazopanib versus Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastasectomy: A Trial of the ECOG-ACRIN Cancer Research Group (E2810). Journal of Clinical Oncology, 37, 4502-4502. [Google Scholar] [CrossRef]
|
|
[42]
|
Procopio, G., Apollonio, G., Cognetti, F., Miceli, R., Milella, M., Mosca, A., et al. (2019) Sorafenib versus Observation Following Radical Metastasectomy for Clear-Cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-Label RESORT Study. European Urology Oncology, 2, 699-707. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Lee, C.C., Tey, J.C.S., Cheo, T., Lee, C.H., Wong, A., Kumar, N., et al. (2020) Outcomes of Patients with Spinal Metastases from Renal Cell Carcinoma Treated with Conventionally-Fractionated External Beam Radiation Therapy. Medicine, 99, e19838. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
DiBiase, S.J., Valicenti, R.K., Schultz, D., Xie, Y., Gomella, L.G. and Corn, B.W. (1997) Palliative Irradiation for Focally Symptomatic Metastatic Renal Cell Carcinoma. The Journal of Urology, 158, 746-749.
|
|
[45]
|
Klausner, G., Troussier, I., Biau, J., Jacob, J., Schernberg, A., Canova, C., et al. (2019) Stereotactic Radiation Therapy for Renal Cell Carcinoma Brain Metastases in the Tyrosine Kinase Inhibitors Era: Outcomes of 120 Patients. Clinical Genitourinary Cancer, 17, 191-200. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Taunk, N.K., Spratt, D.E., Bilsky, M. and Yamada, Y. (2015) Spine Radiosurgery in the Management of Renal Cell Carcinoma Metastases. Journal of the National Comprehensive Cancer Network, 13, 801-809. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Zaorsky, N.G., Lehrer, E.J., Kothari, G., Louie, A.V. and Siva, S. (2019) Stereotactic Ablative Radiation Therapy for Oligometastatic Renal Cell Carcinoma (SABR ORCA): A Meta-Analysis of 28 Studies. European Urology Oncology, 2, 515-523. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Dengina, N., Mitin, T., Gamayunov, S., Safina, S., Kreinina, Y. and Tsimafeyeu, I. (2019) Stereotactic Body Radiation Therapy in Combination with Systemic Therapy for Metastatic Renal Cell Carcinoma: A Prospective Multicentre Study. ESMO Open, 4, e000535. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Barata, P.C., Mendiratta, P., Kotecha, R., Gopalakrishnan, D., Juloori, A., Chao, S.T., et al. (2018) Effect of Switching Systemic Treatment after Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 16, 413-419.e1. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
ASCO GU 2020: Combined Dual Checkpoint Inhibition and Stereotactic Body Radiotherapy in the Metastatic Renal Cell Carcinoma Setting (RADVAX RCC).
https://www.urotoday.com/conference-highlights/asco-gu-2020/asco-gu-2020-kidney-cancer/119323-asco-gu-2020-combined-dual-checkpoint-inhibition-and-stereotactic-body-radiotherapy-in-the-metastatic-renal-cell-carcinoma-setting-radvax-rcc.html
|
|
[51]
|
Twyman-Saint Victor, C., Rech, A.J., Maity, A., Rengan, R., Pauken, K.E., Stelekati, E., et al. (2015) Radiation and Dual Checkpoint Blockade Activate Non-Redundant Immune Mechanisms in Cancer. Nature, 520, 373-377. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
ASCO GU 2020: Nivolumab in Combination with Stereotactic Body Radiotherapy in Pre-Treated Patients with Metastatic Renal Cell Carcinoma (NIVES).
https://www.urotoday.com/conference-highlights/asco-gu-2020/asco-gu-2020-kidney-cancer/119278-asco-gu-2020-nivolumab-in-combination-with-stereotactic-body-radiotherapy-in-pre-treated-patients-with-metastatic-renal-cell-carcinoma-nives.html
|
|
[53]
|
Motzer, R.J., Rini, B.I., McDermott, D.F., Arén Frontera, O., Hammers, H.J., Carducci, M.A., et al. (2019) Nivolumab Plus Ipilimumab versus Sunitinib in First-Line Treatment for Advanced Renal Cell Carcinoma: Extended Follow-up of Efficacy and Safety Results from a Randomised, Controlled, Phase 3 Trial. The Lancet Oncology, 20, 1370-1385. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Garcia, J.A. and Rini, B.I. (2007) Recent Progress in the Management of Advanced Renal Cell Carcinoma. CA: A Cancer Journal for Clinicians, 57, 112-125. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Choueiri, T.K. and Motzer, R.J. (2017) Systemic Therapy for Metastatic Renal-Cell Carcinoma. New England Journal of Medicine, 376, 354-366. [Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
Allard, C.B., Gelpi-Hammerschmidt, F., Harshman, L.C., Choueiri, T.K., Faiena, I., Modi, P., et al. (2015) Contemporary Trends in High-Dose Interleukin-2 Use for Metastatic Renal Cell Carcinoma in the United States. Urologic Oncology: Seminars and Original Investigations, 33, 496.e11-496.e16. [Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Negrier, S., Escudier, B., Lasset, C., Douillard, J., Savary, J., Chevreau, C., et al. (1998) Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma. New England Journal of Medicine, 338, 1272-1278. [Google Scholar] [CrossRef] [PubMed]
|
|
[58]
|
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., et al. (2007) Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 356, 2271-2281. [Google Scholar] [CrossRef] [PubMed]
|
|
[59]
|
Escudier, B., Eisen, T., Stadler, W.M., Szczylik, C., Oudard, S., Siebels, M., et al. (2007) Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma. New England Journal of Medicine, 356, 125-134. [Google Scholar] [CrossRef] [PubMed]
|
|
[60]
|
Motzer, R.J., Hutson, T.E., Tomczak, P., Michaelson, M.D., Bukowski, R.M., Rixe, O., et al. (2007) Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. New England Journal of Medicine, 356, 115-124. [Google Scholar] [CrossRef] [PubMed]
|
|
[61]
|
Roskoski, R. (2017) Vascular Endothelial Growth Factor (VEGF) and VEGF Receptor Inhibitors in the Treatment of Renal Cell Carcinomas. Pharmacological Research, 120, 116-132. [Google Scholar] [CrossRef] [PubMed]
|
|
[62]
|
Sternberg, C.N., Davis, I.D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J., et al. (2010) Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial. Journal of Clinical Oncology, 28, 1061-1068. [Google Scholar] [CrossRef] [PubMed]
|
|
[63]
|
Frampton, J.E. and Keating, G.M. (2008) Bevacizumab: In First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma. BioDrugs, 22, 113-120. [Google Scholar] [CrossRef] [PubMed]
|
|
[64]
|
Motzer, R.J., Hutson, T.E., Cella, D., Reeves, J., Hawkins, R., Guo, J., et al. (2013) Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. New England Journal of Medicine, 369, 722-731. [Google Scholar] [CrossRef] [PubMed]
|
|
[65]
|
Escudier, B., Porta, C., Bono, P., Powles, T., Eisen, T., Sternberg, C.N., et al. (2014) Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib versus Sunitinib in Patients with Metastatic Renal Cell Carcinoma: PISCES Study. Journal of Clinical Oncology, 32, 1412-1418. [Google Scholar] [CrossRef] [PubMed]
|
|
[66]
|
Choueiri, T.K., Halabi, S., Sanford, B.L., Hahn, O., Michaelson, M.D., Walsh, M.K., et al. (2017) Cabozantinib versus Sunitinib as Initial Targeted Therapy for Patients with Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. Journal of Clinical Oncology, 35, 591-597. [Google Scholar] [CrossRef] [PubMed]
|
|
[67]
|
Wiechno, P., Kucharz, J., Sadowska, M., Michalski, W., Sikora-Kupis, B., Jonska-Gmyrek, J., et al. (2018) Contemporary Treatment of Metastatic Renal Cell Carcinoma. Medical Oncology, 35, Article No. 156. [Google Scholar] [CrossRef] [PubMed]
|
|
[68]
|
Motzer, R.J., Escudier, B., McDermott, D.F., George, S., Hammers, H.J., Srinivas, S., et al. (2015) Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 373, 1803-1813. [Google Scholar] [CrossRef] [PubMed]
|
|
[69]
|
Atkins, M.B. and Tannir, N.M. (2018) Current and Emerging Therapies for First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma. Cancer Treatment Reviews, 70, 127-137. [Google Scholar] [CrossRef] [PubMed]
|
|
[70]
|
Ornstein, M.C. and Rini, B.I. (2018) Radical Shifts in the First-Line Management of Metastatic Renal Cell Carcinoma. Nature Reviews Clinical Oncology, 16, 71-72. [Google Scholar] [CrossRef] [PubMed]
|
|
[71]
|
Hahn, A.W., Klaassen, Z., Agarwal, N., Haaland, B., Esther, J., Ye, X.Y., et al. (2019) First-Line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis. European Urology Oncology, 2, 708-715. [Google Scholar] [CrossRef] [PubMed]
|
|
[72]
|
Yasuda, S., Sho, M., Yamato, I., Yoshiji, H., Wakatsuki, K., Nishiwada, S., et al. (2013) Simultaneous Blockade of Programmed Death 1 and Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Induces Synergistic Anti-Tumour Effect in Vivo. Clinical and Experimental Immunology, 172, 500-506. [Google Scholar] [CrossRef] [PubMed]
|
|
[73]
|
Dirkx, A.E.M., Egbrink, M.G.A.o., Castermans, K., Schaft, D.W.J., Thijssen, V.L.J.L., Dings, R.P.M., et al. (2006) Anti‐Angiogenesis Therapy Can Overcome Endothelial Cell Anergy and Promote Leukocyte‐Endothelium Interactions and Infiltration in Tumors. The FASEB Journal, 20, 621-630. [Google Scholar] [CrossRef] [PubMed]
|
|
[74]
|
Plimack, E.R., Rini, B.I., Stus, V., Gafanov, R., Waddell, T., Nosov, D., et al. (2020) Pembrolizumab plus Axitinib versus Sunitinib as First-Line Therapy for Advanced Renal Cell Carcinoma (RCC): Updated Analysis of Keynote-426. Journal of Clinical Oncology, 38, 5001. [Google Scholar] [CrossRef]
|
|
[75]
|
Rini, B.I., Plimack, E.R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., et al. (2019) Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 380, 1116-1127. [Google Scholar] [CrossRef] [PubMed]
|
|
[76]
|
Motzer, R.J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M.T., et al. (2019) Avelumab Plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 380, 1103-1115. [Google Scholar] [CrossRef] [PubMed]
|
|
[77]
|
Rini, B.I., Powles, T., Atkins, M.B., Escudier, B., McDermott, D.F., Suarez, C., et al. (2019) Atezolizumab Plus Bevacizumab versus Sunitinib in Patients with Previously Untreated Metastatic Renal Cell Carcinoma (IMmotion151): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial. The Lancet, 393, 2404-2415. [Google Scholar] [CrossRef] [PubMed]
|